CoChat

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Purpose: The heterodimeric transcription factor HIF-2 is arguably the most important driver of clear cell renal cell carcinoma (ccRCC). Although considered undruggable, structural analyses at the University of Texas Southwestern Medical Center (UTSW, Dallas, TX) identified a vulnerability in the α subunit, which heterodimerizes with HIF1β, ultimately leading to the development of PT2385, a first-in-class inhibitor. PT2385 was safe and active in a first-in-human phase I clinical trial of patients with extensively pretreated ccRCC at UTSW and elsewhere. There were no dose-limiting toxicities, and disease control ≥4 months was achieved in 42% of patients. Patients and Methods: We conducted a prospective companion substudy involving a subset of patients enrolled in the phase I clinical trial at UTSW (n = 10), who were treated at the phase II dose or above, involving multiparametric MRI, blood draws, and serial biopsies for biochemical, whole exome, and RNA-sequencing studies. Results: PT2385 inhibited HIF-2 in nontumor tissues, as determined by a reduction in erythropoietin levels (a pharmacodynamic marker), in all but one patient, who had the lowest drug concentrations. PT2385 dissociated HIF-2 complexes in ccRCC metastases, and inhibited HIF-2 target gene expression. In contrast, HIF-1 complexes were unaffected. Prolonged PT2385 treatment resulted in the acquisition of resistance, and we identified a gatekeeper mutation (G323E) in HIF2α, which interferes with drug binding and precluded HIF-2 complex dissociation. In addition, we identified an acquired TP53 mutation elsewhere, suggesting a possible alternate mechanism of resistance. Conclusions: These findings demonstrate a core dependency on HIF-2 in metastatic ccRCC and establish PT2385 as a highly specific HIF-2 inhibitor in humans. New approaches will be required to target mutant HIF-2 beyond PT2385 or the closely related PT2977 (MK-6482).

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1459

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Cited by

See all 206

Metadata

Authors
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., Yuan, Q., Xi, Y., Zhang, Y., Chang, J., Fatunde, O., Arriaga, Y., Frankel, A. E., Kalva, S., Zhang, S., McKenzie, T., Reig Torras, O., Figlin, R. A., Rini, B. I., McKay, R. M., Kapur, P., Wang, T., Pedrosa, I., & Brugarolas, J.
Affiliations
  • Harold C. Simmons Comprehensive Cancer Center (US)
  • 2Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
  • The University of Texas Southwestern Medical Center (US)
  • Cedars-Sinai Medical Center (US)
  • Cleveland Clinic (US)
Corresponding author
Brugarolas, James
Venue
Clinical Cancer Research
Published
2020-02-14
Volume
26
Issue
4
Pages
793-803
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2986293512
Cited by
188
References
54
Citations by year
2026: 18 · 2025: 29 · 2024: 26 · 2023: 27 · 2022: 36 · 2021: 39 · 2020: 12
FWCI
6.94
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Cancer Prevention and Research Institute of Texas (RP160440)
  • NIH (P50CA196516)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
PT2385, HIF-2α, clear cell renal cell carcinoma, acquired drug resistance, gatekeeper mutation, TP53 mutation, HIF-1, metastatic renal cell carcinoma
MeSH terms
Multiparametric Magnetic Resonance Imaging, Endothelial PAS Domain-Containing Protein 1, Aged, Carcinoma, Renal Cell, Female, Humans, Indans, Kidney Neoplasms, Male, Middle Aged, Prospective Studies, Sulfones, Clinical Trials, Phase I as Topic, Drug Resistance, Neoplasm, Basic Helix-Loop-Helix Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1459
The paper
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., Yuan, Q., Xi, Y., Zhang, Y., Chang, J., Fatunde, O., Arriaga, Y., Frankel, A. E., Kalva, S., Zhang, S., . . . Brugarolas, J. (2020). HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.